Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

enGene Holdings Inc. - Common Stock (NQ: ENGN )

6.320 +0.360 (+6.04%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,972
Open 6.100
Bid (Size) 6.300 (1)
Ask (Size) 6.600 (2)
Prev. Close 5.960
Today's Range 6.030 - 6.320
52wk Range 4.420 - 18.40
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire

Performance

YTD
-31.00%
-31.00%
1 Month
-23.76%
-23.76%
3 Month
+1.12%
+1.12%
6 Month
-21.00%
-21.00%
1 Year
-10.99%
-10.99%

More News

Read More
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From enGene Holdings Inc.
Via Business Wire
Why Are EnGene Holdings Shares Trading Lower Friday?
Via Benzinga
Why enGene Holdings Stock Is Trading Higher
Via Benzinga
enGene Announces $60 Million Private Placement Financing
From enGene Holdings Inc.
Via Business Wire
IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
From enGene Holdings Inc.
Via Business Wire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024
Via InvestorPlace
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
enGene to Present at the Jefferies Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
From enGene Holdings Inc.
Via Business Wire
Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Edges Higher; QuidelOrtho Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.